idea-015 · feasibility deck
Every slide states a condition that would have to be true, then reports where it stands using the candidate file's own claim and its own confidence tag. A deck never upgrades a tag, invents a number, or recommends anything, and there is no ask slide.
The chair: engineering. The people who have to put a ratcheting lock inside a silicone ring that a woman wears for months, clean it between wears, prove it still holds, and hand a reviewer the bench file that says so.
How to read this: every slide is a condition, not a conclusion. a bracketed claim reference points at the numbered claim of knowledge-base/candidates/idea-015.md whose position it names, with the tag that claim carries there right now; [no claim] means nothing in the file speaks to this. Quantities appear only where a claim carries them, and the blanks are left visible. See docs/deck-spec.md.
First build, at stage: verified. Nothing in this file is a bench measurement. Every verified claim here is a register fact — a classification, a clearance, two patent filing dates, a fee schedule. The device has never been built, so the feasibility evidence base is, precisely, empty; what this deck can do is say what the empty places are shaped like.
Would have to be true: A single SKU would have to present a supporting outer diameter that a clinician can set anywhere across a continuous range spanning the standard ring-pessary size ladder, lock it there, read the set value off the device, and reproduce that value at a later visit — replacing a stocked multi-size fitting set.
Where it stands: The range the device has to span is not specified anywhere in the file as a requirement, but two claims bound it. A competitor's registered study enrolled current ring or Gellhorn pessary users "inclusive of sizes 1.5"-3.5"" [claim 21: unconfirmed], which is the nearest thing to a stated ladder span in this file. The shape and size families an incumbent single clearance covers — ring, ring-with-support, ring-with-knob, Marland, Gellhorn and cube across Stage I-III prolapse — are on record in the K231786 Indications for Use [claim 26: verified]. The regulatory definition the device must satisfy is "a removable structure placed in the vagina to support the pelvic organs" [claim 1: verified]. What the file does not carry: a required supporting force, a diameter resolution or step size, a number of adjustment cycles, a labelled reuse life, or a retention-force spec [no claim]. None is estimated here. That the multi-size fitting set is a real product category to be displaced is evidenced indirectly by K153422, a cleared "Panpac Disposable Pessary Fitting Set" noted under [claim 5: unconfirmed].
What would settle it: A design-input specification written against the published ring-pessary size ladder and against measured intra-abdominal loading — a human engineering act, not a lookup. The size ladder itself should be taken from the incumbent labelling (K231786's IFU is retrievable at accessdata.fda.gov) rather than from a competitor's trial eligibility.
If it's false: If a continuous mechanism cannot span the whole ladder, the device replaces part of a fitting set rather than all of it, and the single-SKU inventory argument — which is the entire commercial premise, carried by [claim 22: unconfirmed] and [claim 27: unverified] — becomes a two-or-three-SKU argument worth much less.
Would have to be true: The lock would have to hold its set diameter under repeated Valsalva loading and months of wear without backing off, and the resulting fit would have to be retained at least as well as the fixed-size pessary it replaces.
Where it stands: Mechanical support of a prolapsed compartment is the incumbent mechanism and is not in question [claim 1: verified]. The lock is. There is no bench or materials data of any kind behind lock retention [claim 25: unconfirmed], and the file records this as an attempted check with no available instrument — no connector in this repo reaches a bench-performance question about an unbuilt device. The magnitude the mechanism has to reach is set by a competitor's protocol rather than by this file: NCT04275089's primary outcomes compared retention of the study device against the subject's own current pessary during Valsalva [claim 21: unconfirmed], which is the right endpoint and the right comparator to adopt. That a re-adjusted fit outperforms the next discrete size is the central clinical bet [claim 23: unconfirmed], unverifiable by construction for a device that does not exist, and the baseline it must beat is itself unsettled — the source behind [claim 15: unconfirmed] reports 20-60% discontinuation at 24 months rather than the 30-50% at 12 months the claim states, and it excluded women who failed initial fitting.
What would settle it: A bench rig applying cyclic Valsalva-magnitude loading to a locked joint over the labelled reuse life, measuring diameter drift. Then the prospective comparative fitting study the Factor 6 row names. A human lead worth taking first: the non-tagging MAUDE sweep of HHW returned 102 adverse-event reports between 2021 and 2026 — no denominator and no rate, but the cheapest available read on how marketed pessaries actually fail in the body (recorded under [claim 25: unconfirmed]).
If it's false: If the lock drifts, the device is worse than the fixed-size pessary it replaces on the one dimension patients notice, and the clinical argument inverts: an adjustable device that loses its adjustment is a failure mode conventional pessaries do not have.
Would have to be true: The build would have to be sized for Class II performance standards plus bench and biocompatibility evidence, with no clinical investigation — and the mechanism would have to be readable as a change in geometry and materials rather than as a new technological characteristic.
Where it stands: The class is confirmed: 21 CFR 884.3575 classifies the vaginal pessary as Class II (performance standards) and FDA assigns product code HHW [claim 1: verified] — checked against two independent primary sources, and explicitly tied to this file's stated intended use, so a later indication change invalidates it. The file is equally explicit that this establishes what HHW is, not that a mechanically set and locked diameter stays inside it — a pre-submission question, not a database lookup. Whether HHW even requires a 510(k) or is premarket-notification exempt subject to 21 CFR 884.9 is not established [claim 2: unconfirmed], and the file diagnoses why precisely: the classification connector surfaces no exemption field, the regulation text carries no exemption language, and 16 Substantially Equivalent decisions in the code do not settle it because voluntary clearances inside exempt codes are common. The De Novo branch is live because no cleared adjustable-diameter predicate was identified [claim 5: unconfirmed]. The available analog is single-use and non-adjustable: ProVate, cleared for temporary non-surgical management of POP [claim 3: verified], which the file correctly treats as an analog rather than a predicate for the mechanism. Three confirmed prolapse-pessary clearances exist to argue equivalence against [claim 26: verified]. That no clinical investigation is needed is [claim 34: unverified].
What would settle it: The FDA Product Classification database record for HHW read for its "510(k) Exempt" flag — a connector change or a human lookup. Then a pre-submission meeting, which is the only instrument that answers whether the ratcheting lock keeps this inside HHW.
If it's false: A De Novo reading changes what gets built, not just when: special controls would have to be proposed rather than inherited, and Factor 1 (Regulatory, 15%) and Factor 7 (Capital intensity, 10%) both move together — the file says this one question drives the whole spread on Factor 7.
Would have to be true: A ratchet with enough holding force to resist Valsalva loading would have to be realisable without any rigid component breaching the medical-grade silicone envelope that touches the mucosa — because a ratchet needs rigid detents and silicone is an elastomer, and a material interface at the mucosal surface is a different biocompatibility submission from a moulded silicone ring.
Where it stands: [claim 35: unverified] — this deck put it on record; nothing in the file addressed how the ratchet is physically realised. The mechanism: description says only "a ratcheting internal band" inside a reusable medical-grade silicone ring-with-support, which leaves the rigid-element question open. The consequence is already named as the principal bench-evidence risk: a reusable device with a mechanical joint carries a cleaning-validation and biocompatibility burden that a solid silicone ring does not, with crevice contamination, biofilm and loss of lock as the three failure modes, and no bench or materials data informing any of them [claim 25: unconfirmed]. The file carries no value for holding force, detent count, cycle life or crevice dimension [no claim].
What would settle it: A materials and mechanism trade study, then a physical prototype — an engineering act with no connector behind it. ISO 10993 evaluation is scoped by the answer: a fully encapsulated ratchet is a prolonged mucosal-contact assessment on one material family, and a breaching one is an assessment on two plus the interface.
If it's false: If the ratchet cannot be encapsulated, the device acquires a second patient-contacting material, a crevice at the mucosal surface, and a cleaning-validation problem that [claim 25: unconfirmed] already calls the principal bench risk — and the cheap silicone-moulding cost story behind [claim 24: unconfirmed] goes with it.
Would have to be true: Before any patient is fitted, a bench file would have to show three things: the lock holds its diameter over the labelled reuse life under cyclic loading, the joint can be cleaned to a validated endpoint by the routine the patient will actually use, and the materials pass ISO 10993 for prolonged mucosal contact.
Where it stands: None of the three exists, and the file says so without hedging [claim 25: unconfirmed]: no bench, no materials data, no available instrument in this repo. The cleaning half has a second condition behind it that this deck put on record — that the patient's routine is the conventional soap-and-water pessary routine with no added disinfection step and no clinician reprocessing [claim 37: unverified] — because cleaning validation has to be run against the routine that will actually be labelled, not an idealised one. Retention endpoint precedent exists in a competitor's completed study [claim 21: unconfirmed].
What would settle it: A bench cleaning-validation protocol and an ISO 10993 biocompatibility programme on a real joint, plus cyclic lock-retention testing — commissioned laboratory work, named as such in the Factor 6 row. Reading the 102 MAUDE narratives for HHW first would sharpen the protocol at no cost.
If it's false: This is the slide Tier 3 sits immediately downstream of. If the bench file cannot be produced, nothing further happens — no fitting, no study, and no agent in this repo greenlights what comes next in any case. The desirability deck's Slide 6 is explicitly downstream of this slide, not parallel to it.
Would have to be true: The clinician would have to be able to set and re-lock the diameter with the device in situ, without withdrawing it — and the device would have to be manufacturable as a two-part assembly at a unit cost materially below what the device is paid.
Where it stands: In-situ adjustability is [claim 36: unverified], and it is the hinge between a real workflow change and a cosmetic one: if the device must be withdrawn to adjust, the visit runs exactly as trial-and-error fitting runs today and the premise behind [claim 27: unverified] collapses into the status quo. The mechanism: text says a failed fit is corrected "by re-adjusting the same device within the same visit rather than by withdrawing it", which asserts the workflow without specifying the access. Manufacturability against the payment ceiling is [claim 24: unconfirmed], and the file notes it is untestable in both directions at once right now: no bill-of-materials or contract-manufacturing quote on the cost side, and an unconfirmed allowed amount on the ceiling side [claim 11: unconfirmed]. Sterilisation and shelf life are not addressed by any claim [no claim]; conventional pessaries are supplied clean rather than sterile, but nothing in this file establishes that, and it is not asserted here.
What would settle it: A usability study on a physical prototype with fitting clinicians, run as IEC 62366 human-factors work rather than a demo. A contract-manufacturing quote on a silicone overmoulded two-part assembly with a ratcheting detent settles the cost side and tests [claim 24: unconfirmed] in the same pass.
If it's false: If adjustment requires withdrawal, the device is a fitting-set replacement and nothing more — still a real inventory argument, but the fitting-success argument in [claim 23: unconfirmed] loses its mechanism and the desirability deck's load-bearing condition loses its subject.
Would have to be true: The design would have to reach a working mechanism without touching what live art already covers — and the art field around the ratcheting lock itself would have to have been looked at.
Where it stands: It has not been looked at. No comprehensive freedom-to-operate or patent-landscape search was performed for a ratcheting, lockable, clinician-adjustable-diameter intravaginal support device, for the locking mechanism, or for the single-SKU fitting workflow; the field for the core novelty is unexamined, not clear [claim 18: unconfirmed] — and the file states plainly that nothing an agent can run will close this, because patent is a single-record lookup with no landscape capability anywhere in the connector surface. What is known constrains the design at its edges rather than its centre: US 11,865,033, filed 2021-05-26, naive term to 2041-05-26, not expired, covering an improved collapsible construction and a finger-receiving removal loop [claim 16: verified] — verified as a register fact and nothing more, with issued claim scope explicitly not confirmed and any infringement reading ruled out as a legal opinion this repo may not generate. It has already steered this design away from a collapse-for-removal feature, which is a design constraint accepted rather than a workaround. US 6,189,535 "Deflatable vaginal pessary", filed 1993-04-02 and expired 2013-04-02, puts one size-variable pessary concept in expired art [claim 17: verified] — comfort on practising that concept, and the reverse on patenting near it, which is Slide 5 of the viability deck and [claim 32: unverified].
What would settle it: A commissioned professional FTO search on the ratcheting diameter lock — a paid, multi-week item and the single most expensive gap in the file — and a USPTO/Patent Center pull for the issued claims, assignee, legal status and maintenance state of US 11,865,033.
If it's false: FTO carries the rubric's only automatic kill. An unexamined field cannot trigger it, which is exactly why the correct posture today is neither blocked nor clear; but a live patent reading on the lock would end the programme regardless of every other factor, and no amount of bench work substitutes for looking.
Every condition above with nothing verified behind it. Read this slide first. The verified claims this deck leans on (1, 3, 16, 17, 26) say what FDA calls a pessary, what two other companies were cleared to sell, and when two patents were filed. None of them is a measurement of anything this device would have to do.
If only one thing from this chair could be checked: whether a ratchet that holds under Valsalva loading can be built inside an unbroken silicone envelope — [claim 35: unverified], with [claim 25: unconfirmed] immediately behind it.
Why this one rather than the others. The regulatory questions on Slide 3 are expensive and slow but they are answerable by asking; the FTO question on Slide 7 is the most consequential open item in the whole file but it is a purchase order, not an engineering risk. This one is the only condition on this deck that could make the device physically impossible in its intended form rather than merely slower or more expensive — and it sits upstream of almost everything else here: the biocompatibility scope, the cleaning validation, the unit cost behind [claim 24: unconfirmed], and whether in-situ adjustment on Slide 6 is even mechanically available. It is also cheap to attack: a trade study and a printed mock-up, before anyone buys a pre-submission or an FTO search.
Naming it is not a recommendation, a gate, or a kill.